Search Results
Mar 18, 2026, 07:44 ET Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
imipridone compounds including Modeyso™ (dordaviprone), a protease activator of the mitochondrial caseinolytic protease P (ClpP) and a dopamine D2 receptor (DRD2) inhibitor."Jazz is presenting research at AACR that highlights how we are advancing our oncology portfolio with pace and rigor to deliver differentiated
More news about: Jazz Pharmaceuticals plc
Oct 30, 2025, 17:31 ET Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
patients. Additionally, the launch of emerging therapies such as PD-1 inhibitor (Nivolumab), Aurora A kinase inhibitor (Alisertib), C ClpP agonist and DRD2 antagonist (ONC206), among others, are further expected to propel the market.
More news about: DelveInsight Business Research, LLP
Sep 09, 2025, 07:45 ET Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
given once weekly. Modeyso is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and also inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis and alters mitochondrial metabolism, leading to restored histone
More news about: Jazz Pharmaceuticals plc
Aug 20, 2025, 16:15 ET Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
given once weekly. Modeyso is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and also inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone
More news about: Jazz Pharmaceuticals plc
Aug 06, 2025, 15:07 ET Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
given once weekly. Modeyso is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and also inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone
More news about: Jazz Pharmaceuticals
Jul 11, 2025, 02:00 ET Arasan kündigt die sofortige Verfügbarkeit seiner Total IP für Embedded USB2 (eUSB2) mit Controller und PHY an
beeinträchtigt. Arasan ist das einzige Unternehmen, das eine komplette Suite von USB 2.0 IP-Produkten anbietet, einschließlich USB 2.0 Host, Hub, Gerät, OTG, DRD, eUSB und PHY. Arasan bietet auch die HSIC-Option für Chip-zu-Chip-Verbindungen über USB. „Mit 25 Jahren USB-Erfahrung und über 150 USB-Halbleiter-Lizenznehmern
More news about: Arasan Chip Systems, Inc.
Jul 11, 2025, 02:00 ET Arasan Announces immediate availability of its Total IP for Embedded USB2 (eUSB2) with Controller and PHY
impacted by eUSB2. Arasan is the only company to offer the complete suite of USB 2.0 IP products including the USB 2.0 Host, Hub, Device, OTG, DRD, eUSB and PHY. Arasan also offers the HSIC option for chip to chip connections over USB. "With 25 years of USB experience and over 150 USB Semiconductor
More news about: Arasan Chip Systems, Inc.
Jul 11, 2025, 02:00 ET Arasan anuncia la disponibilidad inmediata de su IP total para USB2 integrado (eUSB2) con controlador y PHY
afectados por eUSB2. Arasan es la única empresa que ofrece la gama completa de productos IP USB 2.0, incluyendo host, concentrador, dispositivo, OTG, DRD, eUSB y PHY. Arasan también ofrece la opción HSIC para conexiones de chip a chip a través de USB. "Con 25 años de experiencia en USB y más de
More news about: Arasan Chip Systems, Inc.
Jul 11, 2025, 02:00 ET Arasan annonce la disponibilité immédiate de son IP total pour l'USB2 embarqué (eUSB2) avec contrôleur et PHY
Arasan est la seule entreprise à proposer une gamme complète de produits USB 2.0 IP, y compris l'hôte USB 2.0, le concentrateur, le dispositif, OTG, DRD, eUSB et PHY. Arasan propose également l'option HSIC pour les connexions puce à puce via USB. « Avec 25 ans d'expérience dans le domaine de l'USB
More news about: Arasan Chip Systems, Inc.
Jul 10, 2025, 23:55 ET Arasan、コントローラとPHYを備えた組み込みUSB2（eUSB2）向けトータルIPの即時提供を発表
2.0ソフトウェア・プログラミング・モデルを変更する必要はありません。eUSB2は、USB2 D+およびD-と同じ2つのデータ・ライン構成（eD+およびeD-）も使用します。Vbusと電力供給はeUSB2の影響を受けません。 Arasanは、USB 2.0ホスト、ハブ、デバイス、OTG、DRD、eUSB、PHYを含むUSB 2.0 IP製品の完全なスイートを提供する唯一の企業です。Arasanは、USB経由のチップ間接続用のHSICオプションも提供しています。 「25年にわたるUSBの経験と150社を超えるUSB半導体ライセンシーを擁するArasanは、トータルUSB IPソリューションの提供における先駆者です。」
More news about: Arasan Chip Systems, Inc.
Jul 10, 2025, 19:00 ET Arasan 宣佈立即推出內嵌式 USB2 (eUSB2) 的完整 IP，包括控制器和 PHY
2.0 軟件程式模型。eUSB2 也使用與 USB2 D+ 和 D- 相同的兩種數據線配置 D+ 和 eD-。eUSB2 不會影響 Vbus 和電源傳輸。 Arasan 是唯一提供完整 USB 2.0 IP 產品套件的公司，包括 USB 2.0 Host、Hub、Device、OTG、DRD、eUSB 和 PHY。Arasan 也提供 HSIC 選項，可透過 USB 進行晶片對晶片連接。 「Arasan 擁有 25 年的 USB 經驗和超過 150 間 USB 半導體授權廠商，是提供全方位 USB IP 解決方案的先驅。」 經過矽晶驗證的 eUSB 控制器
More news about: Arasan Chip Systems, Inc.
Jul 10, 2025, 19:00 ET 아라산, 즉시 사용 가능한 eUSB2용 Total IP (컨트롤러•PHY 포함) 공개
eUSB2는 USB2와 동일하게 두 개의 데이터 라인 구성(eD+, eD-)을 사용하며, 이는 각각 USB2의 D+, D-에 해당한다. Vbus 및 전력 공급은 eUSB2의 영향을 받지 않는다. 아라산은 USB 2.0 Host, Hub, Device, OTG, DRD, eUSB 및 PHY를 포함한 USB 2.0 IP 전 제품 시리즈를 제공하는 유일한 기업이다. 또한 칩 간 USB 연결을 위한 HSIC(High-Speed Inter-Chip) 옵션도 함께 제공하고 있다. "25년의 USB 경험과 150개 이상의 USB
More news about: Arasan Chip Systems, Inc.
Jul 10, 2025, 19:00 ET Arasan ने Controller और PHY के साथ अपने Embedded USB2 (eUSB2) के लिए Total IP की तुरंत उपलब्धता की घोषणा की है
और eD- का उपयोग करता है। eUSB2 से Vbus और पॉवर डिलीवरी प्रभावित नहीं होती है। Arasan एकमात्र ऐसी कंपनी है जो USB 2.0 होस्ट, हब, डिवाइस, OTG, DRD, eUSB और PHY सहित USB 2.0 IP उत्पादों का पूरा सेट प्रदान करती है। USB पर चिप से चिप कनैक्शनों के लिए Arasan द्वारा HSIC विकल्प भी प्रदान किया जाता है।
More news about: Arasan Chip Systems, Inc.
Jul 09, 2025, 15:23 ET Arasan Announces immediate availability of its Total IP for Embedded USB2 (eUSB2) with Controller and PHY
impacted by eUSB2. Arasan is the only company to offer the complete suite of USB 2.0 IP products including the USB 2.0 Host, Hub, Device, OTG, DRD, eUSB and PHY. Arasan also offers the HSIC option for chip to chip connections over USB. "With 25 years of USB experience and over 150 USB
More news about: Arasan Chip Systems, Inc.
May 28, 2025, 17:31 ET Merck's WELIREG Entry Brings New Momentum to Pheochromocytomas and Paragangliomas Therapeutics Market | DelveInsight
SSTR2 agonists and antagonists, alpha-emitting agents, and SSTR2 analogs. Other approaches under investigation involve Dopamine Receptor D2 (DRD2) modulators and ClpP agonists. Each therapy employs distinct mechanisms of action, offering promising advantages and making them key candidates
More news about: DelveInsight Business Research, LLP
Apr 23, 2025, 16:15 ET Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
Dordaviprone (ONC201) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). Dordaviprone's unique mechanism of action includes alterations of key epigenetic modifications such as reversal of H3 K27me3-loss, which is the hallmark
More news about: Jazz Pharmaceuticals plc
Apr 21, 2025, 16:05 ET Jazz Pharmaceuticals Completes Acquisition of Chimerix
DordaviproneDordaviprone (ONC201) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). Dordaviprone's unique mechanism of action includes alterations of key epigenetic modifications such as reversal of H3 K27me3-loss, which is the hallmark
More news about: Jazz Pharmaceuticals plc